Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 14/20 | 0.58 |
| ▸ | ITGB2 | P05107 | 13/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 13/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.32 |
| ▸ | ITGAV | P06756 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.32 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17991431 | 1.00 | ITGAL (0.58) | ITGALITGB2ICAM1ITGA4ITGB1 | |
| SCHEMBL22296921 | 1.00 | ITGAL (0.58) | ITGALITGB2ICAM1ITGA4ITGB1 | |
| SCHEMBL4756091 | 1.00 | ITGAL (0.58) | ITGALITGB2ICAM1ITGA4ITGB1 | |
| SCHEMBL12169805 | 1.00 | ITGAL (0.58) | ITGALITGB2ICAM1ITGA4ITGB1 | |
| SCHEMBL22296859 | 0.92 | ITGAL (0.48) | ITGALITGB2ICAM1ITGA4ITGB1 | |
| SCHEMBL17991450 | 0.92 | ITGAL (0.57) | ITGALITGB2ICAM1ITGA4ITGB1 | |
| SCHEMBL23153584 | 0.91 | ITGAL (0.62) | ITGALITGB2ICAM1ITGA4ITGB1 | |
| SCHEMBL19157868 | 0.91 | ITGAL (0.62) | ITGALITGB2ICAM1ITGA4ITGB1 | |
| SCHEMBL12169811 | 0.91 | ITGAL (0.62) | ITGALITGB2ICAM1ITGA4ITGB1 | |
| SCHEMBL17991456 | 0.91 | ITGAL (0.62) | ITGALITGB2ICAM1ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220702-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE BIOSCIENCE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160220702-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE BIOSCIENCE INC. (US) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220702-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB2 11/4885ICAM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.